对乙酰氨基酚联合布洛芬与单药相比对全髋关节置换术后24小时患者自控吗啡用量的影响:PANSAID随机临床试验
PANSAID是一项在丹麦6家医院开展的随机、盲法、安慰剂对照4组试验,纳入556例全髋关节置换术患者,比较对乙酰氨基酚1000 mg联合布洛芬400 mg、单用对乙酰氨基酚1000 mg、单用布洛芬400 mg、半强度对乙酰氨基酚500 mg联合布洛芬200 mg(均口服每6小时一次,术后24小时,术前1小时开始)对24小时吗啡消耗量和90天内严重不良事件的影响。结果显示,联合组中位吗啡消耗量20 mg,单用对乙酰氨基酚组36 mg,两组中位差16 mg(99.6% CI 6.5至24;P<.001);联合组与单用布洛芬组中位差6 mg(99.6% CI -2至16;P=.002),未达统计学显著。含布洛芬组严重不良事件比例15%,单用对乙酰氨基酚组11%,相对风险1.44(97.5% CI 0.79至2.64;P=.18)。作者认为联合方案较单用对乙酰氨基酚显著减少吗啡用量,但较单用布洛芬无临床重要改善,单用布洛芬可能是合理的早期术后口服镇痛选择。
要点
- 全髋关节置换术后24小时内,对乙酰氨基酚1000 mg联合布洛芬400 mg组中位吗啡消耗量20 mg,单用对乙酰氨基酚1000 mg组36 mg,中位差16 mg(99.6% CI 6.5至24;P<.001)。
- 联合组与单用布洛芬400 mg组中位吗啡消耗量差6 mg(99.6% CI -2至16;P=.002),未达统计学显著,作者认为无临床重要改善。
- 含布洛芬组90天内严重不良事件比例15%,单用对乙酰氨基酚组11%,相对风险1.44(97.5% CI 0.79至2.64;P=.18),无统计学显著增加。
- 作者认为单用布洛芬可能是全髋关节置换术后早期术后口服镇痛的合理选择。
- 所有方案均为口服每6小时一次,术后24小时,术前1小时开始。
适用人群与场景
- 接受全髋关节置换术的患者,来自丹麦6家医院,2015年12月至2017年10月纳入,随访90天。
处置流程与药物剂量
- 对乙酰氨基酚1000 mg联合布洛芬400 mg口服每6小时一次,术后24小时,术前1小时开始(PCM+IBU组,n=136)。
- 对乙酰氨基酚1000 mg联合安慰剂口服每6小时一次,术后24小时,术前1小时开始(PCM组,n=142)。
- 布洛芬400 mg联合安慰剂口服每6小时一次,术后24小时,术前1小时开始(IBU组,n=141)。
- 半强度对乙酰氨基酚500 mg联合布洛芬200 mg口服每6小时一次,术后24小时,术前1小时开始(HS-PCM+IBU组,n=140)。
研究设计与关键结果
- 研究类型:随机、盲法、安慰剂对照4组试验,6家丹麦医院,纳入556例全髋关节置换术患者,90天随访。
- 主要终点之一:24小时吗啡消耗量(患者自控镇痛),PCM+IBU组中位20 mg(99.6% CI 0-148),PCM组36 mg(99.6% CI 0-166),IBU组26 mg(99.6% CI 2-139),HS-PCM+IBU组28 mg(99.6% CI 2-145)。
- PCM+IBU组与PCM组中位差16 mg(99.6% CI 6.5至24;P<.001);PCM组与HS-PCM+IBU组中位差8 mg(99.6% CI -1至14;P=.001);PCM+IBU组与IBU组中位差6 mg(99.6% CI -2至16;P=.002)。
- PCM+IBU组与HS-PCM+IBU组中位差8 mg(99.6% CI -2至16;P=.005),PCM组与IBU组中位差10 mg(99.6% CI -2至16;P=.004),经多重比较和2个共同主要终点校正后未达统计学显著。
- IBU组与HS-PCM+IBU组中位差2 mg(99.6% CI -10至7;P=.81),无显著差异。
- 另一主要终点:90天内严重不良事件比例,含布洛芬组15%,单用对乙酰氨基酚组11%,相对风险1.44(97.5% CI 0.79至2.64;P=.18)。
证据类型、等级与局限
- 证据类型:随机、盲法、安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在全髋关节置换术后早期口服镇痛中,单用布洛芬可能是合理的选择。
- 作者认为,对乙酰氨基酚联合布洛芬较单用对乙酰氨基酚显著减少24小时吗啡消耗量,但较单用布洛芬无临床重要改善。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Multimodal postoperative analgesia is widely used but lacks evidence of benefit.
OBJECTIVE: Investigate beneficial and harmful effects of 4 nonopioid analgesics regimens.
DESIGN, SETTING, AND PARTICIPANTS: Randomized, blinded, placebo-controlled, 4-group trial in 6 Danish hospitals with 90-day follow-up that included 556 patients undergoing total hip arthroplasty (THA) from December 2015 to October 2017. Final date of follow-up was January 1, 2018.
INTERVENTIONS: Participants were randomized to receive paracetamol (acetaminophen) 1000 mg plus ibuprofen 400 mg (n = 136; PCM + IBU), paracetamol 1000 mg plus matched placebo (n = 142; PCM), ibuprofen 400 mg plus matched placebo (n = 141; IBU), or half-strength paracetamol 500 mg plus ibuprofen 200 mg (n = 140; HS-PCM + IBU) orally every 6 hours for 24 hours postoperatively, starting 1 hour before surgery.
MAIN OUTCOMES AND MEASURES: Two co-primary outcomes: 24-hour morphine consumption using patient-controlled analgesia in pairwise comparisons between the 4 groups (multiplicity-adjusted thresholds for statistical significance, P < .0042; minimal clinically important difference, 10 mg), and proportion of patients with 1 or more serious adverse events (SAEs) within 90 days (multiplicity-adjusted thresholds for statistical significance, P < .025).
RESULTS: Among 559 randomized participants (mean age, 67 years; 277 [50%] women), 556 (99.5%) completed the trial and were included in the analysis. Median 24-hour morphine consumption was 20 mg (99.6% CI, 0-148) in the PCM + IBU group, 36 mg (99.6% CI, 0-166) for PCM alone, 26 mg (99.6% CI, 2-139) for IBU alone, and 28 mg (99.6% CI, 2-145) for HS-PCM + IBU. The median difference in morphine consumption between the PCM + IBU group vs PCM alone was 16 mg (99.6% CI, 6.5 to 24; P < .001); for the PCM-alone group vs HS-PCM + IBU, 8 mg (99.6% CI, -1 to 14; P = .001); and for the PCM + IBU group vs IBU alone, 6 mg (99.6% CI, -2 to 16; P = .002). The difference in morphine consumption was not statistically significant for the PCM + IBU group vs HS-PCM + IBU (8 mg [99.6% CI, -2 to 16]; P = .005) or for the PCM-alone group vs IBU alone (10 mg [99.6% CI, -2 to 16]; P = .004) after adjustment for multiple comparisons and 2 co-primary outcomes. There was no significant difference between the IBU-alone group vs HS-PCM + IBU (2 mg [99.6% CI, -10 to 7]; P = .81). The proportion of patients with SAEs in groups receiving IBU was 15%, and in the PCM-alone group, was 11%. The relative risk of SAE was 1.44 (97.5% CI, 0.79 to 2.64; P = .18).
CONCLUSIONS AND RELEVANCE: Among patients undergoing THA, paracetamol plus ibuprofen significantly reduced morphine consumption compared with paracetamol alone in the first 24 hours after surgery; there was no statistically significant increase in SAEs in the pooled groups receiving ibuprofen alone vs with paracetamol alone. However, the combination did not result in a clinically important improvement over ibuprofen alone, suggesting that ibuprofen alone may be a reasonable option for early postoperative oral analgesia.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02571361.
参考来源
- Thybo KH, Hägi-Pedersen D, Dahl JB, et al. Effect of Combination of Paracetamol (Acetaminophen) and Ibuprofen vs Either Alone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty: The PANSAID Randomized Clinical Trial. JAMA. 2019. PMID: 30747964. doi:10.1001/jama.2018.22039
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。